Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

NCT05906576 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-22

No results posted yet for this study

Summary

Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.

Conditions

  • Crohn Disease

Interventions

DRUG

Infliximab

Infliximab in the treatment of Crohn's disease in children

Sponsors & Collaborators

  • Taizhou Mabtech Pharmaceutical Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Wu Jie · Beijing Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2026-11-30
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05906576 on ClinicalTrials.gov